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CLINICAL STUDIES
Exercise-Induced Myocardial Ischemia in Patients With Coronary
Artery Disease: Lack of Evidence for Platelet Activation or Fibrin
Formation in Peripheral Venous Blood
JOSEPH J. MARCELLA, MD, ALLEN B. NICHOLS, MD, FACC, LYNNE L. JOHNSON, MD,
JOHN OWEN, MD, DENNIS S. REISON, MD, KAREN L. KAPLAN, MD,
PAULJ.CANNON,MD,FACC
New York, New York
The hypothesis that exercise-induced myocardial isch-
emia is associated with abnormal platelet activation and
fibrin formation or dissolution was tested in patients with
coronary artery disease undergoing upright bicycle stress
testing. In vivo platelet activation was assessed by ra-
dioimmunoassay of platelet factor 4, beta-thrombo-glob-
ulin and thromboxane 8 2, In vivo fibrin formation was
assessed by radioimmunoassay of fibrinopeptide A, and
fibrinolysis was assessed by radioimmunoassay ofthrom-
bin-increasable fibrinopeptide 8 which reflects plasmin
cleavage of fibrin I. Peripheral venous concentrations of
these substances were measured in 10 normal subjects
and 13 patients with coronary artery disease at rest and
during symptom-limited peak exercise. Platelet factor 4,
beta-thromboglobulin and thromboxane 8 2 concentra-
tions were correlated with rest and exercise catechol-
amine concentrations to determine if exercise-induced
elevation of norepinephrine and epinephrine enhances
platelet activation. Left ventricular end-diastolicand end-
systolic volumes, ejection fraction and segmental wall
Transient platelet activation could be related to exercise-
induced myocardial ischemia by the following mechanisms.
First, flow-limiting platelet aggregates and fibrin strands
could form at sites of atherosclerotic coronary artery lesions.
If this occurs, thromboxane Az, released by aggregating
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motion were measured at rest and during peak exercise
by first pass radionuclide angiography. All patients with
coronary artery disease had documented exercise-in-
duced myocardial ischemia manifested by angina pec-
toris, ischemic electrocardiographic changes, left ven-
tricular segmental dyssynergy and a reduction in ejection
fraction.
Rest and peak exercise plasma concentrations were
not significantly different for platelet factor 4, beta-
thromboglobulin, thromboxane 8 2, fibrinopeptide A and
thrombin-increasable fibrinopeptide 8. Peripheral ve-
nous concentrations of norepinephrine and epinephrine
increased significantly (p < 0.001) in both groups of
patients. The elevated catecholamine levels did not lead
to detectable platelet activation. This study demonstrates
that enhanced platelet activation, thromboxane release
and fibrin formation or dissolution are not detectable in
peripheral venous blood of patients with coronary dis-
ease during exercise-induced myocardial ischemia.
platelets, could provoke coronary artery vasoconstnctIon
(1-4). Second, platelet activation could occur in the mi-
crovasculature of ischemic or previously infarcted myo-
cardial segments (5-8). Both platelet aggregation and
thromboxane Az release can be potentiated by elevated cate-
cholamine concentrations resulting from exercise (9-11).
Platelet survival and platelet aggregation studies have
been repeatedly performed in attempts to link platelet ac-
tivation to clinical events such as angina pectoris and myo-
cardial infarction (12-15). Many of these studies have sug-
gested that platelets of patients with ischemic heart disease
are abnormally reactive, but quantification of in vivo platelet
activation has not been possible in these studies (16-18).
Green et al. (19) first used radioimmunoassay of proteins
released from platelets to study platelet activation in patients
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with coronary artery disease at rest and during exercise.
They reported that platelet factor 4 levels in peripheral ve-
nous blood were increased in patients with coronary artery
disease during myocardial ischemia induced by exercise.
However, other workers failed to confirm the finding that
platelet protein levels were elevated during exercise-induced
myocardial ischemia (20-23). In several of these conflicting
studies, peripheral venous levels of only one platelet protein,
either platelet factor 4 or beta-thromboglobulin, were mea-
sured (19-21,23). Determination of the levels of both plate-
let proteins in each blood sample has been suggested as a
useful method for distinguishing platelet release that occurs
in vivo from that which may occur in vitro during collection
and processing of the blood samples (24,25).
The objective of this investigation was to determine if
in vivo platelet secretion, fibrinogen/fibrin proteolysis and
thromboxane Az release are detectable in patients with coro-
nary artery disease during exercise-induced myocardial
ischemia, by measurement of platelet proteins, fibrinopep-
tide A, thrombin-increasable fibrinopeptide Band throm-
boxane Bz in peripheral venous blood. The study was de-
signed to compare concentrations of these substances mea-
sured at rest, during exercise-induced myocardial ischemia
and after recovery in patients with coronary artery disease
and in healthy control subjects. The presence of myocardial
ischemia was documented both by radionuclide angiography
and exercise stress electrocardiography.
Methods
Patient Selection
Criteria for exclusion from the study were recent myo-
cardial infarction « 3 months), diabetes mellitus, throm-
bophlebitis, valvular heart disease, congestive heart failure,
atrial fibrillation, chronic lung, renal or liver disease, ane-
mia or any bleeding disorder. Also excluded were patients
who had undergone cardiac surgery and patients with an
implanted pacemaker or other prosthetic device.
Group 1 (control subjects) consisted of 10 healthy male
volunteers (mean age 29 years, range 22 to 46). None of
the control subjects had cardiac symptoms; all had normal
cardiovascular examinations and none were taking med-
ications.
Group 2 (study patients) consisted of 13 men (mean age
55 years, range 36 to 69) with angina pectoris. Six of these
patients had a prior myocardial infarction documented by
electrocardiographic changes and a diagnostic increase in
cardiac serum enzyme levels. Ten of the 13 patients under-
went clinically indicated coronary arteriography and all had
a documented stenosis of at least 70% of the luminal di-
ameter of a major epicardial coronary artery. Of these 10,
1 patient had disease of the left anterior descending artery
only, 4 patients had double vessel disease and 5 patients
had triple vessel disease, including 1 with a left main lesion.
Three patients did not have cardiac catheterization. Two of
these had a myocardial infarction occurring 5 and 60 months,
respectively, before the exercise study. The other patient
developed typical anginal pain, ischemic electrocardio-
graphic changes and regional left ventricular wall motion
abnormalities demonstrated by radionuclide angiography
during stress testing.
Five patients were receiving propranolol, one patient was
receiving timolol and six patients were receiving long-acting
nitrates. Beta-blockers were discontinued 14 hours (range
11 to 19) and nitrates were discontinued 13 hours (range I
to 20) before exercise testing. Of the five patients receiving
propranolol, four had a plasma level less than 2.5 ng/ml
and one had a plasma level of 9.2 ng/ml-Ievels that have
been shown to have a negligible effect on platelet aggre-
gation in vitro (26). Three patients were receiving diuretic
agents that were discontinued 24 hours before exercise test-
ing. None of the patients with coronary artery disease had
experienced an anginal episode during the 72 hours before
exercise testing. None of the patients received anticoagulant
agents, aspirin, dipyridamole, theophylline, hydralazine or
nonsteroidal anti-inflammatory agents or any other drugs
known to affect platelet function during the 2 weeks before
exercise stress testing.
Exercise Protocol
All subjects underwent graded upright exercise testing
on a variable load bicycle ergometer. All patients were
fasting and abstained from caffeinated beverages and smok-
ing for 5 hours before testing. Radionuclide angiography
was performed at rest and during peak exercise by the first
pass technique using a computerized multicrystal scintilla-
tion camera (Baird Atomic System-77) as previously de-
scribed (27). Left ventricular ejection fraction was calcu-
latedfrom background-corrected end-diastolicand end-systolic
counts recorded for a representative cycle as previously
described (27). Left ventricular end-diastolic volume was
calculated by the area-length method of Dodge et al. (28).
From the ejection fraction and end-diastolic volume mea-
surements, the following data were derived: stroke volume
= end-diastolic volume x ejection fraction, and cardiac
output = stroke volume x heart rate. Ventricular volumes
and cardiac output were normalized for body surface area.
Regional wall motion of the anterior, apical and inferior
segments of the left ventricle was evaluated from the re-
gional ejection fraction image that is generated from stroke
volume and end-diastolic analog images of the representa-
tive cardiac cycle.
Electrocardiographic leads 1, 111 and Vs were monitored
continuously and recorded at I minute intervals during the
exercise test and the 10 minute recovery period. Blood pres-
sure was recorded with a cuff sphygmomanometer at rest,
after each 3 minute stage of exercise and during the recovery
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period. Exercise was begun at 50 watts in group 1 and 25
watts in group 2. Work load was increased in 25 watt in-
crements every 3 minutes. Pedaling was maintained at a
constant rate of 50 rpm. For group 1 (control group), ex-
ercise resulted in leg fatigue after a heart rate of 85% of the
predicted maximum was reached. For group 2 (men with
angina pectoris), exercise was terminated when severe dys-
pnea, leg pain, fatigue or angina pectoris occurred. Work
capacity, reported in kilojoules, was calculated by multi-
plying the exercise time (seconds) and watts for each stage
and summing all stages.
Patients were considered to have an ischemic response
to exercise if two of the following three criteria were met:
angina pectoris, ischemic electrocardiographic changes or
development of left ventricular regional wall motion ab-
normalities. The electrocardiographic criterion for an isch-
emic response to exercise was junctional depression of at
least 0.1 mY followed by a horizontal or downsloping ST
segment of at least 80 ms duration (29).
Blood Sampling Protocol
Samples of venous blood were drawn from a vein in the
left antecubital fossa immediately after the rest radionuclide
angiogram, immediately after completion of the exercise
radionuclide angiogram and after a 10 minute recovery pe-
riod while the patient remained in the upright position. A
separate venipuncture with a 21 gauge scalp needle was
used for each sample. Only direct venipunctures with smooth
and rapid withdrawal of blood were considered acceptable;
otherwise, the needle was removed and another venipunc-
ture was performed with a new needle. For measurement
of fibrinopeptide A and platelet protein concentrations, a
multiple sample vacutainer Luer-adapter (Becton-Dickin-
son) was used to collect 9 ml blood directly into a chilled
siliconized glass 10 ml vacutainer tube containing 1 ml
anticoagulant of 1,000 U/ml Trasylol, 1,400 U/ml heparin,
0.10 M adenosine and 0.02 M theophylline in Hepes buff-
ered saline solution (THAT). Blood was then collected into
a 20 ml polypropylene syringe and 9 ml was transferred to
a chilled siliconized 10 ml tube containing 0.1 mg indo-
methacin and 10 to 15 mg Na2EDTA (sodium ethylene-
diaminetetraacetic acid) for measurement of thromboxane
B2. Additionally, 3 ml was transferred to a tube containing
5.4 mg EGTA and 3.6 mg glutathione for measurement of
catecholamines; 3 ml was transferred to a heparinized tube
for measurement of plasma renin activity and 4.5 ml blood
was added to a chilled polystyrene tube containing 0.5 ml
THAT for determination of thrombin-increasable fibrino-
peptide B. The blood tubes were immediately placed on
melting ice and the scalp needle was removed after obtaining
samples.
Blood samples were excluded if a hematoma developed
at the venipuncture site during blood withdrawal, if blood
flow stopped abruptly during withdrawal or if gross hemo-
lysis was apparent in the plasma after centrifugation.
In patients receiving propranolol, 10 ml of blood was
collected into a chilled heparinized 10 ml glass tube for
determination of the plasma propranolol concentration.
Radioimmunoassay of platelet factor 4, beta-throm-
boglobulin, fibrinopeptide A and thrombin-increasable
fibrinopeptide B. Within 45 minutes of collection, each
sample was centrifuged at 1,700 g for 15 minutes at 4°C.
The supernatant plasma was pipetted into two polypropylene
tubes with a siliconized pipette and centrifuged at 49,000
g for 10 minutes at 4°C. Then 0.5 ml of supernatant plasma
from each tube was pipetted into a polypropylene tube and
frozen at - 60°C. Platelet factor 4 and beta-thromboglobulin
assays were performed according to previously described
techniques (30,31). The remaining plasma was decanted
into a polystyrene tube and frozen at - 60°C. After bentonite
adsorption, fibrinopeptide A assay was performed as pre-
viously described (32). The supernatant plasma for throm-
bin-increasable fibrinopeptide B radioimmunoassay was
precipitated with ethanol, dried, reconstituted and assayed
as previously described (33).
Radioimmunoassay of thromboxane B2 • The samples
were initially centrifuged at 3,000 g for 15 minutes at 4°C;
the plasma was then pipetted into a polycarbonate tube and
centrifuged at 49,000 g for 15 minutes at 4°C, then pipetted
into polypropylene tubes and frozen at - 20°C. The plasma
was assayed directly for thromboxane B2 using a specific
antibody donated by Dr. Lawrence Levine of Brandeis Uni-
versity. The cross-reactivity of various prostaglandins or
prostaglandin metabolites was less than 0.1 % for prosta-
glandins E h E2, AI. F2,,, 6-keto-prostaglandin Fl a and 13,14
dihydro-15-keto prostaglandin E2. rm thromboxane B2,
100 to 125 Ci/mmol was obtained from New England Nu-
clear and the unlabeled thromboxane B2 from Upjohn Di-
agnostics. Each assay tube received 100 ILl of plasma or
100 ILl of standard (6 to 1,000 pg of unlabeled thromboxane
8 2 dissolved in Krebs-Ringer-phosphate bicarbonate buffer
with I% bovine serum albumin), and approximately 6,000
countslmin of eH] thromboxane B2 dissolved in 100 ILl of
Tris-buffered saline solution (10 mM, pH 7.4) with 0.1%
gelatin, followed by 100 ILl of rabbit antithromboxane B2
antiserum diluted 1:20,000 in the Tris-buffer. The tubes
were incubated in a shaking water bath at 37°C for 60
minutes and then placed on ice for 5 minutes. Antibody
bound thromboxane B2 was separated from the unbound
ligand by adding 100 ILl of normal rabbit plasma (diluted
1:200 with Tris buffer) followed by 50 ILl of sheep antirabbit
gamma-G globulin. The tubes were incubated at 4°C for 18
hours and then centrifuged at 6,000 g for 30 minutes. The
pellets were washed with 1 ml ice-cold Tris-buffer, centri-
fuged at 6,000 g for 15 minutes, dissolved in 200 ILl of
O.lN NaOH and I ml of Tris buffer was added. The tubes
were decanted into glass scintillation vials. After the ad-
dition of 15 ml of Hydrofluor, the vials were counted in a
Packard Tri-Carb model 3330 liquid scintillationspectrometer.
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Standard curves were analyzed by the method of Rodbard
and Hutt (34), a nonlinear transformation of the logit-log
relation. The initial (zero point) binding was 56.9%; non-
specific binding was 1.2%. The amount of unlabeled throm-
boxane Bz required to displace zero point binding by 10%
was 5 pg; the amount required to displace zero point binding
by 50% was 40 pg. Recovery was determined by adding
known amounts of unlabeled thromboxane Bz (25 to 800
pg) to plasma. Linear regression analysis of the recovery
of standards revealed that y = 1.032x + 181 (r = 0.998,
n = 3), where y is the amount of thromboxane Bz recovered
and x is the amount added. The intraassay coefficient of
variation was 4.7%; the interassay coefficient of variation
was 7.9%.
Assay of norepinephrine and epinephrine. The assay
for norepinephrine and epinephrine was based on the mod-
ification of the procedure described by Passon and Peuler
(35). The samples were centrifuged at 3,000 g for 15 min-
utes at 4°C. The plasma was then pipetted into 5 cc poly-
propylene tubes and frozen at - 20°C. Fifty JLl of plasma
was assayed for norepinephrine and epinephrine; 100 pg of
each catecholamine was added to 1 aliquot of each sample
to serve as an internal standard. Enzymatic O-methylation
was performed by adding the plasma sample and internal
standard to 50 JLl of a reaction mix. The final concentration
of reactants was as follows: 30 mM MgCIz'6HzO; 100 mM
Tris; 0.05 mM benzylhydroxylamine; 10 mM EGTA; 5 JLCi
S-adenosyl-L-methionine-WH] methyl) (9-11 Ci/mmol) and
catechol-O-methyl transferase, 0.11 mg of a standardized
enzyme preparation (22 mg/ml). The assay was then per-
formed according to a previously described technique (36).
Assay of plasma renin activity and propranolol.
Plasma renin activity was measured by the method of Sealey
and Laragh (37). A radioreceptor assay for propranolol was
performed by the method of Bilezikian et al. (38).
Statistical analysis. Logarithmic transformation was
performed on those values not normally distributed: platelet
factor 4, beta-thromboglobulin, fibrinopeptide A, thrombin-
increasable fibrinopeptide Band thromboxane Bz. Rest
hemodynamics and radionuclide volume data for the two
groups were compared by the unpaired t test. Other com-
parisons between and among groups were performed by
analysis of variance. Correlations were determined by linear
regression analysis. Data are reported as mean values ±
Table 1. Hemodynamics at Rest and Peak Exercise
standard deviation. A probability (p) value less than 0.05
was considered significant.
Results
Exercise tests. None of the normal subjects (group 1)
experienced angina pectoris or developed ischemic electro-
cardiographic changes or left ventricular regional wall mo-
tion abnormalities during exercise. All patients with coro-
naryarterydisease(group 2) developed left ventricularregional
wall motion abnormalities during exercise that were detected
by radionuclide angiography. Eleven patients in group 2
experienced angina pectoris during stress testing, and nine
patients developed ischemic electrocardiographic changes.
Diagnostic ST segment depression could not be detected in
three other patients who had left ventricular hypertrophy
with strain pattern, left bundle branch block or nonsustained
ventricular tachycardia with the onset of exercise-induced
angina.
Hemodynamic and ventriculographic changes during
exercise (Table 1). Heart rate at rest and rate-pressure prod-
uct (systolic blood pressure x heart rate) for the two patient
groupsdid not differ significantly. The peak heart rate achieved
during exercise was significantly (p < 0.001) greater for
subjects in group 1. The rate-pressure product at peak ex-
ercise was significantly (p < 0.001) higher in subjects in
group 1 and the mean work capacity was significantly (p <
0.001) lower for patients in group 2.
Table 2 shows the changes in left ventricular volume and
ejection fraction that occurred with exercise. Both groups
of patients experienced a significant (p < 0.01) increase in
end-diastolic volume index during exercise. Neither the mean
values at rest nor the increase in end-diastolic volume index
with exercise were significantly different for the two groups.
End-systolic volume index decreased significantly (p < 0.01)
for subjects in group 1 during exercise; in contrast, end-
systolic volume index increased significantly (p < 0.01) for
patients in group 2. End-systolic volume index was signif-
icantly (p < 0.01) higher at rest and during exercise in the
patients in group 2. Rest ejection fraction values were higher
(p < 0.01) for subjects in group 1 than for patients in group
2. During exercise, ejection fraction increased (p < 0.001)
in the group 1 subjects, whereas ejection fraction in the
Heart Rate
(beats/min)
Rate-Pressure Product
(mm Hg/min)
Work Capacity
(kilojoules)
Group I Group 2 Group 1 Group 2 Group I Group 2
Rest
Exercise
80 ± 11
172 ± 8*
73 ± 18
117 ± 24*t
9.4 ± 1.6 x 103
31.0 ± 4.3 x 103*
9.3 ± 2.2 x J03
18.0 ± 4.6 x 103*t 88 ± 27 36 ± 14t
*p < 0.001 compared with rest value; tp < 0.001 compared with group l.
Values are expressed as mean values ± standard deviation. Group I = control subjects. Group 2 = patients WIthcoronary artery disease
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Table 2. Left Ventricular Volumes and Ejection Fraction at Rest and Peak Exercise
ESVI (ml/rrr') EF (%)
Group 1 Group 2 Group I Group 2 Group 1 Group 2
Rest
Exercise
64 ± 16
72 ± 17*
80 ± 25
97 ± 26*
27 ± 9
21 ± 6*
48 ± 28t
60 ± 27*t
59 ± 6
72 ± 5*
44 ± 13t
41 ± 13*t
*p < 0.05 compared with rest value, t p < 0.01 compared with group 1.
EDVI = end-diastolic volume index, EF = ejection fraction, ESVI = end-systolic volume index: Group 1 = control subjects: Group 2 = patients with coronary artery
disease.
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Figure 2. Thromboxane B2 concentrations measured at rest, peak
exercise and recovery (mean ± standard deviation). Symbols are
identical to those in Figure I. NS = no significant difference
comparing exercise with rest values and recovery with rest values
within each group.
• CORONARY ARTERY DISEASE GROUP
o NORMAL GROUP
increasable fibrinopeptide B during or after exercise-induced
myocardial ischemia.
Catecholamine concentrations and plasma renin ac-
tivity (Table 3). Plasma norepinephrine concentrations at
rest were not significantly different for groups I and 2. In
both groups, plasma norepinephrine increased (p < 0.001)
during exercise. The increase in plasma norepinephrine con-
centrations from rest to exercise was significantly (p <
0.003) smaller in the patients in group 2 with coronary artery
disease. For both groups, concentrations of plasma norepi-
nephrine measured during recovery were not significantly
different from rest concentrations. Plasma epinephrine con-
centrations also increased significantly (p < 0.001) with
exercise and returned to baseline (p = NS) during the re-
covery period. The normal subjects had a higher (p < 0.01)
rest plasma epinephrine concentration than patients with
coronary artery disease. The increase in plasma epinephrine
concentration with exercise was significantly (p < 0.02)
lower in patients with coronary artery disease.
In both groups of patients, plasma renin activity (Table
3) increased (p < 0.001) during exercise. Neither the plasma
renin activity values at rest nor the increase in plasma renin
activity values with exercise was significantly different be-
tween the two groups of patients. Recovery plasma renin
activity values remained elevated (p < 0.001) in both groups
I and 2 compared with rest values. However, the difference
in plasma renin activity levels between groups during the
recovery period was not significant. In the normal group,
NS
I
RECOVERY
NS
I
EXERCISE
~=====::N:=IS.IS-THROMBOGLoeuLlN
========NsI NsI
NsI
PLATELET FACTOR 4
~
...J I::l!"..,z
4
3
2
I
REST
Figure 1. Platelet protein concentration measured at rest, peak
exercise and recovery (mean ± standard deviation). Open circles
denote normal subjects (group I); closed circles denote patients
with coronary artery disease (group 2). The mean platelet factor
4 concentration at rest was higher (p < 0.02) in patients in group
2 compared with subjects in group I. NS = no significant dif-
ference, comparing exercise with rest values and recovery with
rest values within each group.
• CORONARY ARTERY DISEASE GROUP
o NORMAL GROUP
group 2 patients with coronary artery disease decreased (p
< 0.05), The difference in the change of ejection fraction
with exercise between groups I and 2 was highly significant
(p < 0.001).
Platelet protein and thromboxane B2 concentra-
tions. Platelet factor 4 and beta-thromboglobulin concen-
trations (Fig. I) did not change significantly during exercise
or recovery in either group. The mean platelet factor 4
concentration at rest was higher (p < 0.02) in patients in
group 2 compared with subjects in group I. There were no
significant changes in the concentration of thromboxane B2
(Fig. 2) in peripheral venous blood during exercise or re-
covery in either group.
Fibrinopeptide A and thrombin-increasable fibrino-
peptide B (Fig. 3). There were no significant changes in
fibrinopeptide A concentrations between rest and peak ex-
ercise in either group I or 2; however, values obtained
during the recovery periods were elevated (p < 0.02) com-
pared with values at rest. The mean fibrinopeptide A con-
centration at rest was higher (p < 0.01) in patients in group
2 compared with subjects in group I. In group 2, there were
no significant changes in the concentration of thrombin-
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the increase in plasma renin activity during exercise cor-
related with the increase in norepinephrine concentrations
(r == 0.7, P < 0.03); however, this relation was not observed
in patients with coronary artery disease.
Figure 3. Fibrinopeptide A and thrombin-increasable fibrinopep-
tide B concentrations measuredat rest, peakexerciseand recovery
(mean ± standard deviation). Symbols are identical to those in
Figure I. P values refer to comparisons of recovery withrest values
within each group. The mean fibrinopeptide A concentration at
rest was higher (p < 0.01) in patients in group 2 compared with
subjectsin group I. NS == no significant difference compared with
rest value within each group.
Indexes of Platelet Activation in
Myocardial Ischemia
In the present study, three indexes of platelet activation
were used: platelet factor 4 and beta-thromboglobulin, which
are specifically released platelet alpha-granule proteins (42),
and thromboxane B2 , a stable metabolite of thromboxane
A2 , a compound formed from arachidonic acid during plate-
let activation (1,3).
Each exercise test was performed with the patient seated
upright on a bicycle ergometer with the left arm immobilized
to facilitate direct venipuncture. Because previous studies
have shown that repeated withdrawal of blood samples through
indwelling venous catheters causes progressive increases
in platelet protein and fibrinopeptide A concentrations
Discussion
The present study was designed to determine whether
exercise-induced myocardial ischemia in patients with coro-
nary artery disease is associated with abnormal platelet ac-
tivation or fibrin formation or dissolution detectable in pe-
ripheral venous blood by measurement of platelet factor 4,
beta-thromboglobulin, thromboxane B2 , fibrinopeptide A
and thrombin-increasable fibrinopeptide B concentrations.
Previous studies of exercise-induced myocardial ischemia
using this approach have yielded conflicting results (19-
23,39-41). Widely discrepant results in other studies have
been attributed to differences in patient selection, incom-
plete documentation of myocardial ischemia and differences
in venipuncture technique and blood processing methods.
(22,43,44), separate venipunctures were used for the dif-
ferent time points.
Platelet protein concentrations. In the present study,
platelet protein concentrations were not significantly in-
creased in either the patients with coronary artery disease
during exercise-induced myocardial ischemia or in the nor-
mal subjects during maximal exercise. These results are
similar to those reported recently by Mathis et al. (21),
Tamay et al. (23), Stratton et al. (22) and Hughes et al.
(20). Other groups, including Green et al. (19), Mehta and
Mehta (40), Lindenfeld et al. (41) and Hyers et al. (39),
have reported increases in platelet factor 4 or beta-throm-
boglobulin, or both, with exercise. The reasons for the dif-
ferences between the two groups of studies may be related
to differences in blood collection technique; for example,
some of those who found increases with exercise had col-
lected samples through indwelling venous catheters.
Thromboxane B2• Concentrations of thromboxane B2,
which provide a separate index of platelet activation, were
also not increased with exercise in this study. In other stud-
ies, elevations in peripheral venous thromboxane B2 con-
centrations with exercise (45) or at rest (46) have been
reported. In one of these (45), no inhibitor of cyclooxy-
genase (the enzyme that converts arachidonic acid to a cyclic
endoperoxide which can then be converted to thromboxane
A2) was included in the anticoagulant mixture. In the other
study (46), samples may have been collected after the in-
sertion of woven Dacron catheters, which have been re-
ported to increase peripheral venous concentrations of
thromboxane B2 (44,47),
Fibrinopeptide A and thrombin-increasable fibri-
nopeptide B. Proteolysis of fibrinogen during exercise was
assessed by measurement of fibrinopeptide A, which is formed
along with fibrin I when thrombin acts on fibrinogen (33),
and of thrombin-increasing fibrinopeptide B, which is the
product of plasmin action on fibrin 1 (48). In the present
study, there was no significant increase in fibrinopeptide A
during exercise in either the control group or the patient
group.
Thrombin-increasable fibrinopeptide B was measured only
in patients with coronary artery disease and showed no sig-
nificant change during exercise or recovery. This finding is
interesting in view of extensive reports (49-52) on increased
fibrinolytic activity during exercise, as determined by short-
ening of the euglobulin lysis time. Without measurements
of thrombin-increasable fibrinopeptide B in the control group,
it is impossible to know if the failure of thrombin-increasable
fibrinopeptide B to increase in the patients is related to
coronary artery disease (53), or if it indicates that thrombin-
increasable fibrinopeptide B levels reflect a different phe-
nomenon from that detected by the euglobulin lysis time.
Slight, but significant increases were seen in fibrinopeptide
A concentrations in both groups during the recovery period.
These elevations may have been due to the indwelling Teflon
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Table 3. Mean Peripheral Venous Concentrations of Norepinephrine, Epinephrine and Plasma Renin Activity
NE (pg/ml) EPI (pg/ml) PRA (ng/ml per hour)
Group I Group 2 Group I Group 2 Group I Group 2
Rest 504 :!: 155 514 :!: 162 112 :!: 46 64 :!: 31t 1.3 :!: 0.7 1.4 :!: 1.2
Exercise 1,844 :!: 537* 1,204 :!: 711*t 214 :!: 77* 115 :!: 72*t 2.8 :!: 1.8* 2.8 :!: 2.7*
Recovery 639 :!: 146 524 :!: 215 96 :!: 34 61 :!: 33 2.9 :!: 1.5* 2.1 :!: 1.9*
*p < O.llO] compared with rest value; tp < 0.02 compared with group I
EPI = epinephrine; Group I = control subjects; Group 2 = patients with coronary artery disease: NE = norepmephnne: PRA = plasma rerun acnvrty
intravenous catheter required for isotope injections for radio-
nuclide angiography (44). The elevated mean peripheral
venous concentrations of platelet factor 4 and fibrinopeptide
A at rest in patients in group 2 may be due to the presence
of a prior myocardial infarction in many of these patients
(8).
Catecholamine concentrations. Catecholamines, in su-
praphysiologic concentrations, promote platelet aggregation
and secretion in vitro (9-11). Lower concentrations of cate-
cholamines can potentiate the platelet response to agonists,
and thus may have a role in modulating platelet respon-
siveness in vivo (9,11,54). In the present study, norepi-
nephrine and epinephrine concentrations increased signifi-
cantly with exercise in both groups; however, the increases
in catecholamine concentrations were smaller in patients
with coronary artery disease, compared with those in normal
subjects, reflecting the reduced work load attained. Despite
the significant increases in epinephrine and norepinephrine
concentrations with exercise in both patient groups, no sig-
nificant increases were found in the platelet protein con-
centrations during exercise. This is not surprising because
it has been reported that 50 to 100 nM epinephrine is re-
quired for synergism with ADP-induced platelet activation
in vitro (55), and the maximal epinephrine and norepi-
nephrine concentrations reached with exercise were at least
two orders of magnitude lower.
Plasma renin activity. Plasma renin activity increased
significantly in the normal subjects and patients with coro-
nary artery disease, and remained elevated during the re-
covery period. Known stimuli for renin secretion during
exercise include enhanced sympathetic neuron activity (56,57)
and decreased renal blood flow (58), which may also be
mediated by the sympathetic nervous system (57). Plasma
renin activity in normal subjects may remain elevated up to
30 minutes after heavy exercise (59). In the present study,
a significant correlation between the norepinephrine and
plasma renin activity responses to exercise was observed in
group 1 subjects, suggesting that the enhancement of sym-
pathetic neuron activity by exercise led to increased renin
section.
Implications
This study shows that peripheral venous blood concen-
trations of platelet factor 4, beta-thromboglobulin, throm-
boxane B2 , fibrinopeptide A and thrombin-increasable fi-
brinopeptide B are not increased during exercise-induced
myocardial ischemia in patients with coronary artery disease
or in normal subjects during exercise. Thus, enhanced plate-
let activation, fibrin formation and dissolution are not de-
tectable in peripheral venous blood during exercise-induced
myocardial ischemia in patients with coronary artery dis-
ease. These results indicate either that abnormal platelet
activation and fibrin formation do not occur in the coronary
arteries or myocardial microvasculature during exercise-in-
duced myocardial ischemia, or that the changes are quan-
titatively insufficient to cause significant increases in the
peripheral venous concentrations of the substances reflecting
these processes. Studies of arterial and coronary sinus levels
of platelet proteins, thromboxane B2 , fibrinopeptide A and
thrombin-increasable fibrinopeptide B will be required to
resolve this issue. Currently available cardiac catheters cause
artifactual increases of platelet protein and fibrinopeptide A
concentrations, making such a study impractical. However,
studies of heparin-bonded catheters suggest that such cath-
eters may be suitable (47).
We gratefully acknowledge the expert technical assistance of Robert Sciacca,
Lloyd Fleisher, Betty Grossman, Thomas LIm, Carolme Rose and Leonard
Norbert.
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